Infliximab biosimilars get the EC approval

Infliximab biosimilars get the EC approval

Following the EMA’s CHMP recommendation in June, the European Commission has recently approved the first infliximab biosimilars, which are referenced to Remicade. Remsima/Inflectra which was developed by Celltrion Inc. of South Korea, has already shown to be similar to the biosimilar medicine Remicade, a monoclonal antibody that has been authorized in the EU since 1999.

Upcoming Events
Biologics Manufacturing Korea 2019 28 – 30 May 2019, Singapore

Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.

.. Read More